Financials
- Financial year
- 2025
- Total assets
- €7.5m
- Loss
- -€2.7m
- Solvency
- 82.6%
SPICA THERAPEUTICS
ActiveSummary
SPICA THERAPEUTICS has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.2m and a net result of -€2.7m. Its solvency ranks better than 80% of 271 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 1.1% (low).
Overview
Activity
Research and development on biotechnology
NACE 72101
1 site
Size
€7.5mtotal assets 2025
- Staff
- 0.7 FTE
- Equity
- €6.2m
- Loss
- -€2.7m
Turnover not published (abbreviated format)
Structure
- Largest shareholder
- BIOQUBE FACTORY FUND I · 42.2%
- Board
- 8 members
- Holdings
- 1
Auditor: BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES2025 accounts 71 days early
Why 66raises risk2 changes of registered office in 24 monthsLoss of €2.7m (financial year 2025)lowers riskSector: Scientific research and development (NACE 72)Size: total assets €7.5mShow the evidence
Checked score
Score 2025
66
/ 100
Healthy
Probability in this band: 0.55% to 1.5%
Financially better than 53% of its sector peers (NACE 72, small)
Financial strength
Average
Solvency
100
equity 82.6% of total assets
Liquidity
63
short-term debt 15.5% · cash 13.4%
Profitability
0
return on assets -36.7%
Bankruptcy probability, 12 months
1.1%
Low
0%0.5%1.5%4%10%≥ 25%
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
09-2025: 1.0%
10-2025: 1.0%● unchanged vs 09-2025
11-2025: 1.0%● unchanged vs 10-2025
12-2025: 1.0%● unchanged vs 11-2025
01-2026: 1.1%▲ +0.1 percentage points vs 12-2025
02-2026: 1.2%▲ +0.1 percentage points vs 01-2026
03-2026: 1.2%● unchanged vs 02-2026
04-2026: 1.3%▲ +0.1 percentage points vs 03-2026
05-2026: 1.3%● unchanged vs 04-2026highest value
06-2026: 0.2%▼ -1.1 percentage points vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026lowest value
08-2026: 0.2%● unchanged vs 07-2026
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 1.1%▲ +0.9 percentage points vs 09-2026
Credit of up to €400,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Liquidity ample (current ratio 2.14, above the usual 1.5; short-term debt: 15.5% and cash: 13.4% of total assets), and 17.4% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small): better than 85% on solvency, 63% on liquidity and 11% on profitability.
The bankruptcy probability was computed on 29-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Young company
Founded in 2024, 2 years ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 21-05-2026, 71 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
71 days early
← before the deadline
after the deadline →
Searched, nothing found (1)
- Resignation: Impala Consulting Comm.V (director)Appointments: ALTHUARDE LIFE SCIENCES (director)…
- Resignation: Impala Consulting Comm.V (director)Appointment: ALTHUARDE LIFE SCIENCES (director)…
- Resignation: Triangulate GmbH (ceo bestuurder)Gazette deed
Key points
By topic
Board & ownership
- Board
- 8 members
- Largest shareholder
- BIOQUBE FACTORY FUND I · 42.2%
- Auditor
- BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
- ETZERODT AndersDirector
- PARTICIPATIEMAATSCHAPPIJ VLAANDERENDirector
- QBIC VENTURE PARTNERS IIIDirector
- ALTHUARDE LIFE SCIENCESDirector
- Abbey ConsultingDirector
and 3 other directors
Network & group
- Subsidiaries
- 1
- Connected companies
- 4
1 subsidiary
Timeline
- Events
- 10
- Since
- 2024
- 21-05-2026Annual accounts filed
- 13-03-2026Capital & shares · Amendment of the…
- 11-06-2025Resignations: BIOSKILLS, DEBORA DUMONT MANAGEMENT COMPANY and…
Company details
- Sites
- 1
- Legal form
- Public limited company
- Activity
- Research and development on biotechnologyNACE 72101
- Founded
- 26-08-2024
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 43
- Who signs
- Two directors jointly
- Annual meeting
- Second Friday of March at 11:00
- Purpose
- “A. het onderzoek, ontwikkeling, productie, verkoop en exploitatie van biologische…” (deed in Dutch)
Key facts about SPICA THERAPEUTICS
- What is the company number of SPICA THERAPEUTICS?
- 1012.800.853. In Belgium the VAT number is the company number with BE in front: BE 1012.800.853.
- Where is SPICA THERAPEUTICS based?
- The registered office is at Uitbreidingstraat 66, 2600 Antwerpen.Company details
- What does SPICA THERAPEUTICS do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of SPICA THERAPEUTICS?
- Public limited company (NV).
- When was SPICA THERAPEUTICS founded?
- On 26-08-2024.
- Is SPICA THERAPEUTICS still active?
- Yes, SPICA THERAPEUTICS is an active enterprise in the KBO register.
- How many employees does SPICA THERAPEUTICS have?
- On average 0.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of SPICA THERAPEUTICS?
- Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
- Is SPICA THERAPEUTICS profitable?
- In financial year 2025, SPICA THERAPEUTICS made a loss of €2.7m.
- Where can I find the annual accounts of SPICA THERAPEUTICS?
- SPICA THERAPEUTICS filed 1 annual account with the National Bank of Belgium, for financial year 2025.
Companies related to SPICA THERAPEUTICS
Shareholders
- BIOQUBE FACTORY FUND I42.2%
- Flanders Future Techfund17.71%
- QBIC III FUND7.08%
Comparable companies
- H2WINNivelles
- SYNDESI THERAPEUTICSWavre
- PALL ARTELISHoegaarden
- Biogaz du Haut GeerGeer
- AmphiStarGent
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What support did similar companies receive that this one did not?Subsidies How does this company compare with its sector?Sector benchmark
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.